MICROB-PREDICT

MICROBiome-based biomarkers to **PREDICT**
decompensation of liver cirrhosis and treatment response

Project duration
6 ¼ years

Start
01 January 2019

www.microb-predict.eu

Grant amount
15 million €

10 Countries
22 Partners

MICROB-PREDICT

will investigate the human microbiome to identify predictors and mechanisms associated with the development of decompensation of cirrhosis and progression to **acute-on-chronic liver failure (ACLF) and death.**

→ New microbiome-based tests
for better stratification of cirrhosis patients
→ Personalized prediction and prevention
of decompensation and ACLF
→ Clinical trial to predict response to treatment
→ Modern, effective nanobiosensors as
clinical tools with improved specificity
→ More personalized treatment
→ Increased survival times
→ Decreased costs for
the health systems

EF Clif
EUROPEAN FOUNDATION
FOR THE STUDY OF
CHRONIC LIVER FAILURE

UiO : University of Oslo

UNIVERSITAT DE BARCELONA

UNIVERSITY OF COPENHAGEN

cea
FROM RESEARCH TO INDUSTRY

biobyte
solutions

KU LEUVEN

ICN2
Institut Català
de Nanociència
i Nanotecnologia
EXCELENCIA
SEVERO
OCHOA

OUH
Odense University Hospital
Svendborg Hospital

EASL™
The Home of Hepatology

GOETHE
UNIVERSITÄT
FRANKFURT AM MAIN

KING'S
College
LONDON

LUMC
Leids Universitair
Medisch Centrum

INRA
SCIENCE & IMPACT

UNIVERSITY of
DEBRECEN

MAX-PLANCK-GESELLSCHAFT

EMBL

vaiomer
PIONEER IN TISSUE MICROBIOTA

UCL

ELPA
European Liver
Patients' Association

IDIBAPS
Institut
D'Investigacions
Biomèdiques
August Pi i Sunyer

concentris
research management

Picture: Fotolia